Clinical Trials
7 trialsNCT00481091 2023-06-13
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
AbbVie
Phase 1/2 Completed
NCT01087151 2016-11-02
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 2 Completed
NCT01557777 2014-07-04
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 2 Completed
NCT00868413 2013-06-07
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
AbbVie
Phase 1 Completed
NCT01021358 2010-12-20
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
Abbott
Phase 1 Completed
NCT00743028 2010-10-07
Assess the Oral Bioavailability of New ABT-263 Formulations
Abbott
Phase 1 Completed
NCT00918450 2010-02-26
Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen
Abbott
Phase 2 Withdrawn